What Would a Donanemab Approval Mean for Leqembi?

Earlier this month, an FDA advisory committee determined that Eli Lilly’s anti-amyloid antibody donanemab is an effective treatment for Alzheimer’s disease and that its benefits to patients outweigh its risks. Experts are bullish on the therapy and say that approval for donanemab would also benefit the market for Biogen and Eisai’s Leqembi, another anti-amyloid antibody that was approved last year.